O-5: Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study - Arndt Vogel, et al
SO-12: Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040 - Ignacio Melero, et al
SO-13: Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the open-label, phase 2 KEYNOTE-224 study - Arndt Vogel, et al
SO-14: Atezolizumab Plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study - Andrea Casadei-Gardini, et al
SO-15: Impact of sequencing of different treatment modalities on survival outcomes among patients with non-metastatic hepatocellular carcinoma - Firas Baidoun, et al
